VivoSeq
Other

Enterobacteriaceae Infections

9

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Enterobacteriaceae Infections is an early-stage landscape with 9 programs across 4 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Parkedale, Novartis. 4 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

1 program

Phase 3P

Parkedale

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3Pfizer logo

Pfizer

3 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Terminated1 · 50%

Clinical Trials

Trial Activity

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 3·NCT07089186·80 enrolled
Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
Terminated·KKing Faisal Specialist Hospital & Research Center·Phase 3·NCT05258851·29 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)